Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab - Scorecard - MDSpire

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab

  • By

  • Jens Rathmann

  • Hiba Kadhem

  • Mårten Segelmark

  • David Jayne

  • Aladdin J. Mohammad

  • June 16, 2026

  • 0 min

Share

Clinical Scorecard: Hypogammaglobulinaemia in Rituximab-Treated Individuals with ANCA-Associated Vasculitis: A Population-Based Study from Sweden

At a Glance

CategoryDetail
Condition
Key MechanismsClarify the definition of hypogammaglobulinaemia (HG) with specific IgG thresholds.
Target Population
Care Setting

Key Highlights

  • highlight_1

Guideline-Based Recommendations

Diagnosis

    Management

    • A
    • d
    • d
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • r
    • e
    • c
    • o
    • m
    • m
    • e
    • n
    • d
    • a
    • t
    • i
    • o
    • n
    • s
    • b
    • a
    • s
    • e
    • d
    • o
    • n
    • t
    • h
    • e
    • s
    • t
    • u
    • d
    • y
    • '
    • s
    • r
    • e
    • s
    • u
    • l
    • t
    • s
    • r
    • e
    • g
    • a
    • r
    • d
    • i
    • n
    • g
    • m
    • o
    • n
    • i
    • t
    • o
    • r
    • i
    • n
    • g
    • I
    • g
    • G
    • l
    • e
    • v
    • e
    • l
    • s
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Include additional demographic details of the patient population.

        Clinical Best Practices

        • best_practice_1

        Related Resources & Content

        Original Source(s)

        Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab

        • by Jens Rathmann, Hiba Kadhem, Mårten Segelmark, David Jayne, Aladdin J. Mohammad

        • June 16, 2026

        Related Content

        Trial Exclusions May Skew RA Drug Comparisons

        Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.

        The immunopathological spectrum of COVID-19: from cytokine storm to autoimmunity—a systematic review

        HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling